News

A study published today in the New England Journal of Medicine shows that AMX0035, an experimental therapy, has promise for slowing the progression of ALS. AMX0035 is an oral drug that contains two small molecules, which when combined, aim to…

The ALS Canada Research Program is encouraged by the continued momentum seen in ALS research at a time when support for it is more important than ever before. Read about the progress researchers have made in advancing new treatment strategies,…

Hosted on August 26, 2020 this webinar featured panelists: Dr. Gary Armstrong, McGill University Dr. Nicholas Cole, MND Association Dr. Alex Parker, Universite de Montreal Dr. Daniela Zarnescu, University of Arizona This webinar is available in English only.

July 9, 2020 – A study published today in the New England Journal of Medicine shows that an experimental drug, called tofersen, has promise for treating a genetic form of ALS caused by mutations in the gene SOD1. Results from…

ALS Canada is pleased to welcome Catherine Bélanger, Richard Ellis and Lisa Flaifel to our Board of Directors. Comprised of senior leadership volunteers, our Board ensures ALS Canada is well-governed and donor dollars are maximized to serve our charitable purpose.…

With great appreciation, ALS Canada acknowledges the significant contributions of three Board members whose terms have come to an end, even as their commitment to the ALS cause continues. Thank you to Ron Foerster, Dr. Angela Genge and Patrick Merz…

Dr. David Taylor, VP of Research, hosted a webinar on June 16, 2020 exploring the current state of clinical trials in Canada and worldwide. In this 1-hr archived session, you’ll learn about: Phase 3 ALS clinical trials currently…

In early March, members of the ALS community joined ALS Canada in Ottawa for two days of advocacy training and meetings with politicians and other government officials. From people living with ALS  and their caregivers and family members to researchers,…